Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.

View in: PubMed

subject areas

Aged
Antigens, Differentiation, B-Lymphocyte
Antineoplastic Combined Chemotherapy Protocols
Boronic Acids
Bortezomib
Consolidation Chemotherapy
Cytarabine
Daunorubicin
Disease-Free Survival
Drug Administration Schedule
Drug Synergism
Female
Follow-Up Studies
Histocompatibility Antigens Class II
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute
Male
Middle Aged
Peripheral Nervous System
Pyrazines
Remission Induction
Survival Analysis
Treatment Outcome

authors with profiles

Richard A. Larson